Biomarin Pharmaceutical Inc (BMRN)
Days of sales outstanding (DSO)
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Receivables turnover | 4.31 | 3.75 | 4.48 | 4.91 | 4.07 | |
| DSO | days | 84.73 | 97.42 | 81.40 | 74.36 | 89.76 |
December 31, 2024 calculation
DSO = 365 ÷ Receivables turnover
= 365 ÷ 4.31
= 84.73
Biomarin Pharmaceutical Inc's days of sales outstanding (DSO) have shown some fluctuations over the years based on the provided data. The DSO decreased from 89.76 days as of December 31, 2020, to 74.36 days as of December 31, 2021, indicating a more efficient collection of accounts receivable. However, by December 31, 2022, the DSO increased to 81.40 days, suggesting a slight slowdown in the collection of sales.
Subsequently, the DSO further increased to 97.42 days by December 31, 2023, indicating a potential issue with the company's accounts receivable management or an increase in credit sales. However, the DSO improved to 84.73 days by December 31, 2024, showing a partial recovery in the collection efficiency.
Overall, Biomarin Pharmaceutical Inc's DSO trend reflects some variability in the company's ability to collect receivables promptly. Further analysis would be required to understand the underlying reasons for these fluctuations and to assess the company's overall financial health and efficiency in managing its accounts receivable.
Peer comparison
Dec 31, 2024